Myst Therapeutics (Myst), a preclinical stage biotechnology firm centered on creating chosen TIL-based autologous T cell remedy merchandise for most cancers, introduced the appointment of 5 main specialists within the areas of immunotherapy, tumor infiltrating lymphocytes, gene remedy, and oncology diagnostics to its Scientific Advisory Board.

“Myst is fortunate to attract these world-leading immunotherapy and cancer researchers to our advisory board,” stated TJ Langer, President and Chief Executive Officer of Myst. “Their experience and insight will be invaluable for the development and progression of our PuriT product pipeline.”

James Mulé, Ph.D. – Senior Member, Associate Center Director, and Michael McGillicuddy Endowed Chair in Melanoma Research/Treatment at Moffit Cancer Center. Dr. Mulé has pioneered immune cell-based therapies and ushered them from the laboratory by way of Phase I and II medical trials. He additionally leads work to engineer enhancements to cell-based therapies by way of manipulation of tumor microenvironment and immune organic processes. Dr. Mulé acquired his Ph.D. on the Fred Hutchinson Cancer Research Center, and fellowship coaching on the National Cancer Institute.

Michael Lotze, M.D. – Professor of Surgery, Immunology, and Bioengineering, University of Pittsburgh School of Medicine; Vice Chair of Research, Department of Surgery; Associate Director for Strategic Partnerships, University of Pittsburgh Cancer Institute; Asst. Vice Chancellor, UPSHS. Michael Lotze has been a forerunner in immune-oncology and gene remedy for 3 a long time. He initiated the primary gene therapies on the NIH and has handled over 100 sufferers on the University of Pittsburgh. He is a co-inventor on 10 patents, has authored over 500 scientific papers, and revealed quite a few books and chapters on tumor biology and immunology. Dr. Lotz is the previous CSO of Lion Biotechnologies (now Iovance Biotherapeutics).

Myst Therapeutics Appoints Leading Cancer Immunotherapy Experts to Its Scientific Advisory Board

Pamela Ohashi, Ph.D. – Co-Director of the Campbell Family Institute for Breast Cancer Research, Senior Scientist on the Princess Margaret Cancer Centre, Professor within the Departments of Medical Biophysics and Immunology on the University of Toronto, and the Director of the Tumor Immunotherapy Program on the Princess Margaret Cancer Centre. Dr. Ohashi is an knowledgeable on T cell conduct within the tumor microenvironment the place her work has contributed to quite a few Phase I and Phase II medical trials. Dr. Ohashi is the writer of over 150 scientific publications and has acquired quite a few awards, together with the American Association of Immunologists Pharmingen Investigator Award and the National Cancer Institute of Canada’s William E. Rawls Award.

Chantale Bernatchez, Ph.D. – Associate Professor, Department of Melanoma Medical Oncology – Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. Dr. Bernatchez is the director of the MD Anderson TIL Laboratory, the place she leads the event of tumor infiltrating lymphocyte-based therapies. She at the moment helps a significant Phase II medical trial in Stage IV melanoma sufferers, the primary of its sort exterior of the National Cancer Institute, and is planning future trials using novel methods for selling T cell survival and anti-tumor exercise. Chantale acquired her Ph. D. from Laval University, Quebec and carried out postdoctoral coaching at each Laval University and MD Anderson Cancer middle.

Alex Aravanis, M.D., Ph.D. – Dr. Aravanis is the Chief Scientific Officer, Head of R&D, and Co-Founder at GRAIL, the chief in early most cancers detection diagnostics, and is commanding one of many largest medical examine applications in genomic drugs. Previously, Alex was Senior Director, R&D for Illumina, the place he developed medical assays for RNA and DNA evaluation from fastened tissues, entire exome evaluation, massively parallel single cell transcriptomics, and liquid biopsy utilizing cell-free nucleic acids. Dr. Aravanis served as Vice President of Development and Chief Science Officer of Sapphire Energy Inc. and was a Co-Founder and Vice President of Engineering of Pria Diagnostics, LLC. Alex holds a PhD in Electrical Engineering, and an MD from Stanford University.

“These superb researchers are recognized for their significant discoveries and contributions in the field of tumor immunology and immunotherapy,” acknowledged James Mulé, Ph.D., Associate Center Director and Michael McGillicuddy Endowed Chair in Melanoma Research and Treatment at Moffitt Cancer Center. “Their extensive experience in this field will be invaluable to Myst as the company advances its immunotherapy products to the marketplace.”

About the PuriT™ Platform

Clinical proof has demonstrated {that a} sufferers’ tumor infiltrating lymphocytes (TIL) acknowledge tumor particular molecules, site visitors to the tumor, reply to tumor antigen, and selectively eradicate tumors. Clinical research utilizing these cells have proven sturdy goal medical responses in sufferers with superior metastatic illness, together with refractory melanoma, breast, cervical, and colorectal most cancers. Myst’s PuriT platform builds on these successes by enriching and rejuvenating TIL to additional enhance responses. These encouraging outcomes spotlight PuriT™ as an rising modality able to offering customized remedy choices for sufferers spanning a broad spectrum of cancers.

Myst Therapeutics Appoints Leading Cancer Immunotherapy Experts to Its Scientific Advisory Board

View supply model on businesswire.com: https://www.businesswire.com/news/home/20200312005174/en/

Myst Therapeutics
TJ Langer
[email protected]